Recipharm divests bioanalysis business to Center for Translational Research AB further strengthening existing partnership with CTC Clinical Trial Consultants AB

Recipharm, the contract development and manufacturing organisation, and CTC Clinical Trial Consultants have strengthened their partnership with the divestment of Recipharm’s GLP bioanalysis business to the Center for Translational Research AB (CTR) group. CTR is the Uppsala based parent company of CTC Clinical Trial Consultants.

Recipharm and CTC Clinical Trial Consultants partnered in 2017 to form Recipharm Pathway to Clinic, an integrated service that offers a clear, streamlined pathway to first-in-human milestones. As part of the solution, Recipharm performs formulation development and GMP clinical supply manufacture, whilst CTC Clinical Trial Consultants is responsible for early phase clinical trials (Phase 0–IIa).

The GLP bioanalysis laboratory will now continue its assignments as a newly formed company, Lablytica Life Science AB, 100% owned by CTR.

The analytical activities will continue without interruption with the same staff, in the same facilities, using the same instrumentation and most importantly, the same validated analytical methods. David Pekar, Head of Bioanalysis, will continue to lead the team.

Maria Lundberg, VP Global Analytical Development at Recipharm says: “We are pleased to announce this divestment which allows us to focus on delivering a comprehensive offering from medicinal chemistry through to commercial API manufacturing. This step also further improves the Recipharm Pathway to Clinic offering, where Recipharm continues to facilitate clinical trials by developing and supplying the clinical trial material. The GLP laboratory will now operate within the same group as CTC Clinical Trial Consultants which is a far more logical approach and will result in the even more efficient conduct of clinical trials ultimately improving the result for our customers.”

Bengt Dahlström, Chairman of the Board at CTR comments: “Through the formation of Lablytica as a sister company to CTC Clinical Trial Consultants we believe we will be able to offer a more integrated approach and develop the services for our customers using the talented staff and facilities in the GLP bioanalysis business. The partnership with Recipharm provides a complete solution for first-in-human projects.”

Press contacts

Related stories

CTR launches podcast together with SwedenBIO
11 Apr 2022

CTR launches podcast together with SwedenBIO

The first episode of the podcast Idé till patient (Idea to patient) will be released on April 12.

CTR acquires preclinical toxicology company
06 Apr 2021

CTR acquires preclinical toxicology company

Center for Translational Research Sweden AB (CTR) acquires Toxicology Knowledge Team Sweden AB (TKT) further strengthening the CTR group with optimised toxicological support. From April 1, TKT is a fully owned subsidiary to the holding company CTR.